Hosted on MSN11mon
Aurion doses first subject in Phase I/II corneal oedema trial in Canadawith Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor, Y-27632. The treatment involves a one-time, intracameral injection directly into the eye. ABA-1, CLARA is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback